Introduction:
Peptide-oligonucleotide conjugates for oncology are engineered molecules in which a peptide is chemically linked to an oligonucleotide designed to modify a specific biological pathway associated with cancer. The peptide may provide targeting or cell-penetrating functionality, while the oligonucleotide supplies sequence-specific biological activity.
Oligonucleotide therapeutics can selectively interact with RNA or other nucleic-acid targets, but their development is often limited by poor cellular uptake, biological instability, tissue distribution, and intracellular delivery. Peptide conjugation is one strategy being investigated to overcome these barriers.
The overall concept can be summarized as:
Peptide targeting/penetration → cellular uptake → intracellular trafficking → oligonucleotide release or activity → molecular target modulation → therapeutic effect
Cancer cells often show altered receptor expression, signaling pathways, and molecular dependencies, which can potentially be exploited for selective delivery or gene modulation. At ResolveMass Laboratories Inc., our scientists work daily on the analytical characterization, impurity profiling, and CMC support of complex peptide and oligonucleotide molecules. This article explains how these conjugates work, what makes them difficult to develop, and what sponsors should plan before an IND.
Summary:
- Peptide-oligonucleotide conjugates for oncology combine a targeting or cell-penetrating peptide with an oligonucleotide payload to improve cellular delivery and enable sequence-specific therapeutic activity.
- The peptide can support tumor-cell targeting, receptor recognition, cellular uptake, and intracellular trafficking. The oligonucleotide modulates gene expression.
- Potential payloads include antisense oligonucleotides (ASOs), siRNA, splice-switching oligonucleotides, and other functional nucleic-acid modalities.
- Key development challenges include conjugation efficiency, molecular heterogeneity, linker stability, free peptide/oligonucleotide impurities, aggregation, degradation, and intracellular delivery.
- Characterization needs complementary techniques: HPLC/UPLC, LC-MS, high-resolution mass spectrometry (HRMS), LC-MS/MS, impurity profiling, and stability studies.
- A robust strategy connects molecular identity, purity, conjugation status, degradation pathways, and biological function.
- Analytical data support formulation development, process optimization, comparability, stability assessment, and regulatory documentation.
1: How Do Peptide-Oligonucleotide Conjugates Work in Cancer Therapy?
They combine peptide-mediated cellular delivery with sequence-specific regulation of a disease-associated RNA or gene pathway. The mechanism depends on the peptide, linker, oligonucleotide chemistry, molecular target, and intracellular trafficking pathway.
A simplified mechanism has four stages:
- Target recognition or membrane interaction: a targeting peptide binds a receptor or surface feature more abundant on certain tumor cells, or a cell-penetrating peptide (CPP) facilitates membrane interaction.
- Cellular internalization: the conjugate enters through receptor-mediated uptake or endocytic pathways.
- Intracellular trafficking and payload availability: the oligonucleotide must reach the right compartment and remain sufficiently intact to engage its target.
- Gene or RNA modulation: depending on the payload, the oligonucleotide may promote RNA degradation, alter RNA processing, or suppress translation.
Demonstrating cellular uptake alone is not enough. Effective development requires evidence that the intact conjugate reaches the relevant biological compartment and produces the intended molecular response.
Common Oncology Target Classes
| Target Class | Examples | Oligonucleotide Mechanism |
|---|---|---|
| Oncogenic drivers | KRAS, MYC | mRNA knockdown (ASO/siRNA) |
| Survival signaling | BCL-2, survivin, STAT3 | mRNA knockdown |
| Resistance pathways | Androgen receptor splice variants | Splice modulation or knockdown |
| Immune checkpoint regulation | PD-L1 transcripts | mRNA knockdown |
2: Why Are Peptide-Oligonucleotide Conjugates for Oncology Important?
Their importance lies in combining molecular targeting with programmable nucleic-acid activity in a single therapeutic construct. Cancer biology frequently involves dysregulated genes, oncogenic signaling, and abnormal RNA expression, and oligonucleotides can potentially address targets that are difficult to modulate with conventional small molecules.
Potential advantages include:
- Sequence-specific molecular targeting
- Potential access to previously challenging targets
- Peptide-mediated cellular delivery and possible receptor-directed tumor targeting
- Modular optimization of peptide, linker, and payload
- Targeting and gene modulation within one construct
These advantages do not remove the fundamental delivery challenges. Targeting, uptake, endosomal escape, intracellular stability, and pharmacodynamic activity must be demonstrated rather than assumed. Understanding pharmacokinetics and biodistribution is a central part of that evidence.
3: What Are the Main Components of an Oncology Conjugate?
A conjugate has three core functional elements: a peptide, an oligonucleotide payload, and a linker or conjugation architecture.
| Component | Primary Role | Key Development Considerations |
|---|---|---|
| Peptide | Targeting or cellular delivery | Sequence, charge, receptor interaction, stability |
| Oligonucleotide | Molecular activity | Sequence, chemistry, length, modifications, purity |
| Linker | Connects peptide and oligonucleotide | Stability, cleavage, selectivity, compatibility |
| Conjugation site | Defines molecular architecture | Site specificity, structural integrity |
| Chemical modifications | Improve stability and function | Must be controlled and analytically characterized |
The design is highly modular. Changing the peptide can alter uptake and biodistribution, while changing oligonucleotide chemistry can alter stability, potency, and pharmacokinetics. Analytical characterization must therefore evaluate the complete conjugate, not only its individual parts.
Which Peptides Are Used?
- Cell-penetrating peptides (e.g., arginine-rich): strong uptake, limited selectivity.
- Tumor-homing peptides (e.g., RGD-type integrin binders): improved selectivity, dependent on receptor expression.
- Endosomolytic or pH-responsive peptides: designed to improve endosomal escape.
More cationic peptides tend to increase uptake but may also increase off-target binding, toxicity, and immunogenicity risk.
How Does Linker Chemistry Affect Performance?
Linker chemistry determines intracellular release, plasma stability, and manufacturing reproducibility.
| Linker Type | Release Trigger | Strength | Consideration |
|---|---|---|---|
| Disulfide (cleavable) | Intracellular glutathione | Efficient cytosolic release | Plasma stability must be verified |
| Maleimide-thioether | None | High stability | Possible retro-Michael exchange |
| Click chemistry | None | Selective, high yield | Residual catalyst control |
| Enzyme-cleavable | Lysosomal proteases | Potential tumor-selective release | Variable cleavage kinetics |
4: What Oligonucleotide Payloads Can Be Used?
Payloads include antisense oligonucleotides, siRNA-related constructs, splice-modulating oligonucleotides, and other chemically modified modalities. In oncology they can be designed against oncogenic signaling, tumor-cell survival, aberrant gene expression, RNA splicing, resistance mechanisms, and regulatory RNAs.
Chemistry also influences analytical behavior. Modifications to the sugar, backbone, terminal groups, or bases can change chromatographic retention, ionization efficiency, stability, and fragmentation. The choice between phosphorothioate and phosphodiester backbones, for example, affects nuclease resistance, protein binding, and the number of stereoisomers the analysis must resolve. Payload identity should be established with orthogonal analytical evidence, not retention time alone.
5: What Are the Key Analytical Challenges?
The major challenge is molecular heterogeneity: a conjugate batch can contain the desired product alongside unconjugated components, truncated species, modified forms, and degradation products.
Questions the analytical package must answer:
- Is the intended conjugate molecularly intact?
- Is the expected peptide attached to the correct oligonucleotide, at the correct site?
- What are the levels of unconjugated peptide and free oligonucleotide?
- Are truncated sequences or linker-related impurities present?
- Does oxidation or aggregation occur?
- How does the molecule change during storage?
A single technique rarely answers all of these. Because the conjugate combines two very different molecule classes, orthogonal methods are essential.
| Attribute | Typical Technique | Purpose |
|---|---|---|
| Intact mass and identity | HRMS (LC-MS) | Confirm conjugate mass and stoichiometry |
| Purity and impurities | Ion-pair RP-HPLC/UPLC, IEX-HPLC | Separate free peptide, free oligonucleotide, truncations |
| Sequence confirmation | LC-MS/MS | Verify peptide and oligonucleotide sequences |
| Linker integrity | LC-MS, NMR | Confirm attachment site and chemistry |
| Content and residuals | Quantitative assays, ICP-MS, GC | Assay, counter-ions, residual solvents, elemental impurities |
6: How Can LC-MS and HRMS Characterize These Conjugates?
LC-MS and HRMS provide complementary information on molecular identity, conjugation, impurities, and structural modifications. LC separates the conjugate from related species, while mass spectrometry supplies molecular-weight and structural data. HRMS is especially useful when the mass difference between the intact conjugate and related species is small, or when multiple molecular forms must be distinguished.
A typical workflow:
Chromatographic separation → MS detection → accurate-mass assessment → theoretical mass comparison → impurity assignment → orthogonal confirmation
Large, highly charged peptide-oligonucleotide molecules can generate complex spectra, so sample preparation, MS conditions, and deconvolution are important parts of the method.
7: Which Impurities Should Be Evaluated?
Impurity profiling should cover impurities from the peptide, the oligonucleotide, the conjugation step, and degradation pathways.
| Impurity Category | Examples |
|---|---|
| Peptide-related | Truncated peptide, oxidation, deamidation, sequence variants |
| Oligonucleotide-related | Shortmers, longmers, modified sequences |
| Conjugation-related | Incomplete or incorrect conjugation products |
| Linker-related | Cleavage products, modified linker species |
| Process-related | Residual reagents or synthesis-related impurities |
| Degradation-related | Hydrolysis, oxidation, cleavage, other stress products |
| Physical forms | Aggregates or higher-order species |
The exact profile depends on the molecular design and manufacturing process. Well-characterized reference standards and validated analytical methods are what make impurity limits defensible.
8: Why Is Stability Testing Critical?
Stability testing shows whether the conjugate maintains its chemical integrity, purity, and relevant quality attributes during storage. Studies should track:
- Loss of intact conjugate
- Formation of free peptide or free oligonucleotide
- Oligonucleotide degradation and peptide modification
- Linker cleavage and aggregation
- Changes in chromatographic profile and, where appropriate, biological activity
Forced degradation is especially informative early on because it reveals degradation pathways before long-term data exist, and it shows whether a method can separate the intact conjugate from its degradants. Comparing stressed and unstressed samples with complementary methods is more reliable than relying on one purity value.
9: How Do Regulatory Expectations Apply to Oncology Conjugates?
Regulators generally expect thorough characterization of the full conjugate, defined impurity limits, and a justified control strategy. For an IND, sponsors should be ready to present:
- A defined structure with justification of the linker and conjugation site
- Specifications for identity, purity, potency, and impurities
- Stability data supporting storage conditions
- Nonclinical pharmacology and toxicology supporting the starting dose
- An immunogenicity risk assessment
Reviewing the ICH guidelines for peptide-oligonucleotide conjugates early helps align specifications, stability design, and impurity thresholds with expectations. As programs move toward clinical supply, GMP manufacturing of peptide-oligonucleotide conjugates adds requirements for process control, batch records, and data integrity. Sponsors should confirm current requirements with the relevant authority, since guidance for conjugated oligonucleotides continues to evolve.
What Are the Key Development Risks?
The most important risks are incomplete characterization, poor control of heterogeneity, unstable conjugation chemistry, poor intracellular delivery, and methods that cannot distinguish the intact conjugate from related species.
- Incorrect or incomplete conjugation
- Batch-to-batch molecular variability
- Difficult-to-resolve related substances
- Complex mass-spectrometric profiles
- Linker instability and chemical degradation
- Aggregation
- Insufficient assay specificity or stability-indicating capability
- Disconnect between chemical purity and biological activity
- Endosomal entrapment, off-target toxicity, and immunogenicity
A risk-based analytical strategy identifies these issues earlier and reduces uncertainty. For programs approaching clinical manufacture, GMP manufacturing considerations for conjugates such as scale-up consistency and release testing should be planned in parallel with analytics.
How Does ResolveMass Support Peptide-Oligonucleotide Characterization?
ResolveMass Laboratories Inc. is a Canadian analytical CRO/CDMO with focused expertise in mass spectrometry and complex conjugate analysis, supporting sponsors from early research through regulatory submission. Our integrated approach is designed around molecular characterization, impurity identification, and stability assessment, including:
- HPLC/UPLC separation, LC-MS, HRMS, and LC-MS/MS
- Impurity profiling and molecular-weight confirmation
- Forced degradation and stability-indicating method development
- Structural characterization and comparative analysis of development samples
Conclusion:
Peptide-oligonucleotide conjugates for oncology are an emerging strategy that pairs peptide-mediated delivery or targeting with sequence-specific oligonucleotide activity. Their potential depends on biological design and on controlling molecular identity, conjugation, purity, stability, and degradation.
A robust analytical strategy should connect: molecular characterization → impurity profiling → structural confirmation → forced degradation → stability assessment → development decision-making. As peptide and oligonucleotide technologies converge, comprehensive characterization becomes increasingly important for reliable data and appropriate quality controls.
Frequently Asked Questions:
HRMS provides accurate-mass information that supports confirmation of the expected molecular composition of a peptide-oligonucleotide conjugate.
It can help distinguish the intact conjugate from related molecular species and certain modifications.
HRMS can also support investigation of unexpected or unknown impurities when combined with chromatographic separation.
This makes it valuable for comprehensive molecular characterization and impurity identification.
Potential impurities include truncated peptide or oligonucleotide species, unconjugated peptide or oligonucleotide, and incompletely conjugated products.
Linker-related impurities may also arise from incomplete reactions or linker degradation.
Additional species can result from oxidation, other chemical modifications, or degradation during processing and storage.
A combination of chromatographic and mass-spectrometric techniques can help characterize these impurities.
Forced degradation helps identify potential chemical and physical degradation pathways under controlled stress conditions.
It can reveal degradants associated with the peptide, oligonucleotide, linker, or overall conjugate structure.
The resulting samples can be used to evaluate whether an analytical method separates the intact conjugate from degradation products.
This supports development of reliable stability-indicating analytical methods.
Analytical development should begin during lead selection or early candidate development rather than waiting until the IND stage.
Early characterization helps establish molecular identity, purity, conjugation efficiency, and potential degradation pathways.
It also allows analytical challenges to be identified before process development and regulatory milestones.
Starting early can reduce data gaps, method rework, and unexpected characterization issues later in development.
Reference
- Henke E, Perk J, Vider J, De Candia P, Chin Y, Solit DB, Ponomarev V, Cartegni L, Manova K, Rosen N, Benezra R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nature biotechnology. 2008 Jan;26(1):91-100.https://www.nature.com/articles/nbt1366
- Patutina OA, Bichenkova EV, Miroshnichenko SK, Mironova NL, Trivoluzzi LT, Burusco KK, Bryce RA, Vlassov VV, Zenkova MA. miRNases: Novel peptide-oligonucleotide bioconjugates that silence miR-21 in lymphosarcoma cells. Biomaterials. 2017 Apr 1;122:163-78.https://www.sciencedirect.com/science/article/pii/S0142961217300261
- Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano RL. Antisense inhibition of P-glycoprotein expression using peptide–oligonucleotide conjugates. Biochemical pharmacology. 2000 Jul 1;60(1):83-90.https://www.sciencedirect.com/science/article/pii/S0006295200003105
- Mier W, Eritja R, Mohammed A, Haberkorn U, Eisenhut M. Preparation and evaluation of tumor-targeting peptide− oligonucleotide conjugates. Bioconjugate chemistry. 2000 Nov 20;11(6):855-60.https://pubs.acs.org/doi/abs/10.1021/bc000041k
About the Author
